S&P Futures
5,946.50 +7.75 (+0.13%) Dow Futures
43,470.00 +70.00 (+0.16%) Nasdaq Futures
20,793.25 +25.50 (+0.12%) Russell 2000 Futures
2,336.40 +2.30 (+0.10%) Crude Oil
69.53 +0.14 (+0.20%) Gold
2,643.80 +12.80 (+0.49%)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF)
- PR Newswire
Fosun Pharma Announces 2024Q3 Financial Results
On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024. From January to September 2024, Fosun Pharma achieved revenue of RMB30.91 billion, an increase of about 5.74% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.84 billion, up by
- PR Newswire
Fosun Pharma Announces 2024 Interim Results
On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.3 billion. In
